Notice of Results

Hikma will release its 2009 preliminary results on Wednesday, March 17, 2010

LONDON, 1 March 2010 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (Nasdaq Dubai: HIK), the fast growing multinational pharmaceutical Group, will release its 2009 preliminary results on Wednesday, 17 March 2010. The company will host a presentation for analysts at 9am and a live webcast of the presentation will be available on Hikma's website. www.hikma.com

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Said Darwazah, Chief Executive Officer

Bassam Kanaan, Chief Financial Officer

Susan Ringdal, Investor Relations Director Tel: +44 (0)20 7399 2760

Brunswick Group

Jon Coles / Justine McIlroy Tel: +44 (0)20 7404 5959

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2008, Hikma achieved revenues of $581 million and profit attributable to shareholders of $57 million. For news and other information, please visit www.hikma.com.